Navigation Links
Nanoparticle pinpoints blood vessel plaques
Date:2/6/2014

A team of researchers, led by scientists at Case Western Reserve University, has developed a multifunctional nanoparticle that enables magnetic resonance imaging (MRI) to pinpoint blood vessel plaques caused by atherosclerosis. The technology is a step toward creating a non-invasive method of identifying plaques vulnerable to rupturethe cause of heart attack and strokein time for treatment.

Currently, doctors can identify only blood vessels that are narrowing due to plaque accumulation. A doctor makes an incision and slips a catheter inside a blood vessel in the arm, groin or neck. The catheter emits a dye that enables X-rays to show the narrowing.

However, Case Western Reserve researchers report online today in the journal Nano Letters that a nanoparticle built from a rod-shaped virus commonly found on tobacco locates and illuminates plaque in arteries more effectively and with a tiny fraction of the dye.

More importantly, the work shows that the tailored nanoparticles home in on plaque biomarkers. That opens the possibility that particles can be programmed to identify vulnerable plaques from stable, something untargeted dyes alone cannot.

"From a chemist's point of view, it's still challenging to make nanoparticles that are not spherical, but non-spherical materials are advantageous for medical applications" said Nicole F. Steinmetz, assistant professor of biomedical engineering at Case Western Reserve. "Nature is way ahead of us. We're harvesting nature's methods to turn them into something useful in medicine."

The rod-shaped nanoparticles are made from tobacco mosaic virus, tiny tubular organisms that infect plant cells but are benign outside the plant.

Steinmetz, a specialist in bioengineering plant viruses, teamed with Xin Yu, a professor of biomedical engineering, who specializes in developing MRI techniques to investigate cardiovascular diseases. They created a device that transports and concentrates imaging agents on plaques.

The research team includes: Michael A. Bruckman, a postdoctoral researcher, and Lauren N. Randolph, an undergraduate student, in the Steinmetz lab; Kai Jiang, a PhD student in Yu's lab; and Leonard G. Luyt, assistant professor, and Emily J. Simpson, a PhD candidate, both at department of chemistry at Western University, in London, Ontario.

Elongated nanoparticles have a higher probability of being pushed out of the central blood flow and targeting the vessel wall compared to spheres. Further the shape allows more stable attachment to the plaque, the researchers said.

The virus surface is modified to carry short chains of amino acids, called peptides, that make the virus stick where plaques are developing or already exist. Luyt and Simpson synthesized the peptides.

"The binding allows the particle to stay on the site longer, whereas the sheer force is more likely to wash away a sphere, due to its high curvature," said Yu, an appointee of the Case School of Engineering.

The virus surface was also modified to carry near-infrared dyes used for optical scanning, and gadolinium ions (which are linked with organic molecules, to reduce toxicity of the metal) used as an MRI contrasting agent. They used optical scans to verify the MRI results.

By loading the surface with gadolinium ions instead of injecting them and letting them flow freely in the blood stream, the nanoparticle increases the relaxivityor contrast from healthy tissueby more than four orders of magnitude.

"The agent injected in the blood stream has a relaxivity of 5, and our nanoparticles a relaxivity of 35,000," said Steinmetz who was appointed by the Case Western Reserve School of Medicine.

That's because the nanorod carries up to 2,000 molecules of the contrast agent, concentrating them at the plaque sites. Secondly, attaching the contrast agent to a nanoparticle scaffold reduces its molecular tumbling rates and leads to additional relaxivity benefit, the researchers explained.

While the view is better, they are able to use 400 times less of the contrast agent because it's delivered directly to plaques.

The tobacco virus-based nanoparticle, they said, offers another advantage: Most nanoparticles that have been developed to carry contrast agents are based on synthetic materials, some of which may stay in the body a while.

The tobacco virus is made of protein, which the body is well equipped to handle and flush from the system rapidly.

Steinmetz and Yu, members of the Case Center for Imaging Research, are now proposing to take the work a step further. They want to tailor the nanoparticles to show doctors whether the plaques are stable and require no treatment, or are vulnerable to rupture and require treatment. A rupture sets off the cascade of events that lead to heart attack and stroke.

To do this, they must first find different biomarkers of stable versus vulnerable plaques and coat the nanoparticles with different peptides and contrast agents that enable the MRI to tell one from the other.

"Our understanding of vulnerable plaques is incomplete, but once we can diagnose vulnerable plaques from stable plaques, it will be a paradigm shift in diagnosis and prognosis," Yu said.

In addition to using the technology to find vulnerabilities, it may also useful for delivering medicines and monitoring treatment, the researchers say.


'/>"/>

Contact: Kevin Mayhood
kevin.mayhood@case.edu
216-368-4442
Case Western Reserve University
Source:Eurekalert

Related biology news :

1. UT Arlington bioengineer to create new nanoparticle system to shore up arterial walls
2. Gold nanoparticles help to develop a new method for tracking viruses
3. A magnetic nanoparticles-based method for DNA extraction from the saliva after stroke
4. Oregon scientists offer new insights on controlling nanoparticle stability
5. Ultrasound, nanoparticles may help diabetics avoid the needle
6. Nanoparticles can overcome drug resistance in breast cancer cells
7. Making complex nanoparticles easily reproducible
8. Gold nanoparticles give an edge in recycling CO2
9. Stealth nanoparticles lower drug-resistant tumors defenses
10. Researchers figure out why gold nanoparticles can penetrate cell walls
11. Nanoparticles, pH phoresis could improve cancer drug delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... , ... Parallel 6 , the leading software as a service (SaaS) ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication between ... Using the CONSULT module, patients and physicians can schedule a face to face virtual ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
Breaking Biology Technology: